OmniAb (OABI) Expected to Announce Quarterly Earnings on Tuesday

OmniAb (NASDAQ:OABI) will likely be announcing its earnings results after the market closes on Tuesday, March 18th. Analysts expect the company to announce earnings of ($0.13) per share and revenue of $10.13 million for the quarter. Investors interested in participating in the company’s conference call can do so using this link.

OmniAb Price Performance

OmniAb stock opened at $3.31 on Friday. OmniAb has a 1-year low of $3.05 and a 1-year high of $5.72. The stock’s 50 day moving average price is $3.43 and its 200 day moving average price is $3.82. The company has a market cap of $467.42 million, a PE ratio of -5.34 and a beta of -0.14.

Insider Transactions at OmniAb

In other news, insider Charles S. Berkman sold 25,489 shares of the company’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $3.24, for a total value of $82,584.36. Following the completion of the sale, the insider now owns 343,190 shares of the company’s stock, valued at $1,111,935.60. This represents a 6.91 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Kurt A. Gustafson sold 7,255 shares of the stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $3.67, for a total value of $26,625.85. Following the completion of the transaction, the chief financial officer now directly owns 206,211 shares of the company’s stock, valued at $756,794.37. This represents a 3.40 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 112,260 shares of company stock valued at $376,601 over the last quarter. Company insiders own 8.60% of the company’s stock.

About OmniAb

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.